Ahsun Riaz, Ahmed Gabr, Nadine Abouchaleh, Rehan Ali, Ali Al Asadi, Ronald Mora, Laura Kulik, Kush Desai, Bartley Thornburg, Samdeep Mouli, Ryan Hickey, Frank H. Miller, Vahid Yaghmai, Daniel Ganger, Robert J. Lewandowski, Riad Salem – 18 August 2017 – Does imaging response predict survival in hepatocellular carcinoma (HCC)? We studied the ability of posttherapeutic imaging response to predict overall survival. Over 14 years, 948 patients with HCC were treated with radioembolization.

Ahsun Riaz, Ahmed Gabr, Nadine Abouchaleh, Rehan Ali, Ali Al Asadi, Ronald Mora, Laura Kulik, Kush Desai, Bartley Thornburg, Samdeep Mouli, Ryan Hickey, Frank H. Miller, Vahid Yaghmai, Daniel Ganger, Robert J. Lewandowski, Riad Salem – 18 August 2017 – Does imaging response predict survival in hepatocellular carcinoma (HCC)? We studied the ability of posttherapeutic imaging response to predict overall survival. Over 14 years, 948 patients with HCC were treated with radioembolization.

Tasnuva D. Kabir, Clarissa Ganda, Rikki M. Brown, Dianne J. Beveridge, Kirsty L. Richardson, Vishal Chaturvedi, Patrick Candy, Michael Epis, Larissa Wintle, Felicity Kalinowski, Christina Kopp, Lisa M. Stuart, George C. Yeoh, Jacob George, Peter J. Leedman – 18 August 2017 – Sorafenib remains the only approved drug for treating patients with advanced hepatocellular carcinoma (HCC). However, the therapeutic effect of sorafenib is transient, and patients invariably develop sorafenib resistance (SR).

Xupeng Hong, Elena S. Kim, Haitao Guo – 18 August 2017 – Hepatitis B virus (HBV) infection represents a significant public health burden worldwide. Although current therapeutics manage to control the disease progression, lifelong treatment and surveillance are required because drug resistance develops during treatment and reactivations frequently occur following medication cessation. Thus, the occurrence of hepatocellular carcinoma is decreased, but not eliminated.

Xupeng Hong, Elena S. Kim, Haitao Guo – 18 August 2017 – Hepatitis B virus (HBV) infection represents a significant public health burden worldwide. Although current therapeutics manage to control the disease progression, lifelong treatment and surveillance are required because drug resistance develops during treatment and reactivations frequently occur following medication cessation. Thus, the occurrence of hepatocellular carcinoma is decreased, but not eliminated.

Kwan Man – 17 August 2017

Neehar D. Parikh, Wesley J. Marrero, Jingyuan Wang, Justin Steuer, Elliot B. Tapper, Monica Konerman, Amit G. Singal, David W. Hutton, Eunshin Byon, Mariel S. Lavieri – 17 August 2017 – Nonalcoholic steatohepatitis (NASH) cirrhosis is the fastest growing indication for liver transplantation (LT) in the United States. We aimed to determine the temporal trend behind the rise in obesity and NASH‐related additions to the LT waitlist in the United States and make projections for future NASH burden on the LT waitlist.

E. Sally Ward, Raimund J. Ober – 17 August 2017

Linda Sher, Cristiano Quintini, Sameh Adel Fayek, Peter Abt, Mary Lo, Pui Yuk, Lingyun Ji, Susan Groshen, Jamie Case, Christopher Lee Marsh – 17 August 2017 – Transplantation of liver grafts from donation after cardiac death (DCD) is limited. To identify barriers of DCD liver utilization, all active US liver transplant centers (n = 138) were surveyed, and the responses were compared with the United Network for Organ Sharing (UNOS) data.

Sandy Feng, John Bucuvalas – 17 August 2017 – Impeccable management of immunosuppression is required to ensure the best longterm outcomes for liver transplant recipients. This is particularly challenging for children who arguably need 8 decades of graft and patient survival. Too little risks chronic, often subclinical allo‐immune injury while too much risks insidious and cumulative toxicities. Historically, immunosuppression minimization or withdrawal has been a strategy to optimize the longevity of liver transplant recipients.